Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.01) by 16.83 percent. This is a 2.48 percent increase over losses of $(1.21) per share from the same period last year. The company reported quarterly sales of $3.004 million which beat the analyst consensus estimate of $2.000 million by 50.20 percent. This is a 21.91 percent decrease over sales of $3.847 million the same period last year.